Skip to main content
 

Management

Maria Palasis, Ph.D.
President and Chief Executive Officer

Maria Palasis is President and Chief Executive Officer of 480 Biomedical. Prior to joining 480 Biomedical, Dr. Palasis was R&D director at Boston Scientific, where she managed a portfolio of external biotech and medical device investments and was responsible for the development of new convergence products. Dr. Palasis was as an early member of the team that created the TAXUS® drug-eluting stent, the single most important revenue generator for Boston Scientific at $3B/year. She held a number of positions within Boston Scientific that included strategic planning for the development of advanced combination therapies, managing alliances through clinical trials, and building and directing the company’s centralized infrastructure for the biological testing of drug eluting stent technologies. Maria received her Bachelor of Science and doctorate in chemical engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

Robert Palladino
Chief Financial Officer

Bob Palladino, MBA, is a Senior Executive with 35 years of global strategic and operating experience in Drug Discovery, Genomic Sequencing/Interpretation, Social Media and Registry Patient Data, Stem Cell, Medical Devices/Delivery Systems, Monitoring/Detection, Laparoscopy Procedure Systems, Gynecology, and Oncology. Bob has served as CFO for Claritas Genomics, BioNevia, Corrona, PatientsLikeMe.

Upma Sharma, Ph.D.
Senior Director of Research and Development

Upma Sharma is Director of Research and Development. Dr. Sharma leads product development for Arsenal Medical’s novel foam-based technology platform for treatment of non-compressible hemorrhage, directing a core team through ideation and filing of intellectual property, proof of concept and pre-clinical testing, and clinical system design. Under Dr. Sharma’s scientific leadership, the company gained significant funding from DARPA/ARO for development of this hemorrhage control system. Prior to Arsenal, Dr. Sharma served as a core team member at 480 Biomedical, advancing the company’s innovative biodegradable vascular scaffold from concept to pre-clinical proof-of-concept. Dr. Sharma was responsible for materials selection and drug formulation efforts for the scaffold. Dr. Sharma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Dr. Sharma was awarded a NIH Training Grant in Nanobiology. Dr. Sharma has authored 12 peer-reviewed scientific publications and is an inventor on 10 issued or pending patents.